REGISTER NOW
Determining whether multiple cancer-associated variants occur on the same chromosome (cis) or opposite chromosomes (trans) remains a considerable challenge with conventional short-read sequencing. However, this distinction can have important implications for understanding disease biology and assessing pathogenicity. Long-read nanopore sequencing enables direct haplotype phasing while simultaneously detecting structural variation, DNA methylation and complex genomic rearrangements in a single assay, providing a more comprehensive view of genomic alterations.
This webcast will reveal how long-read sequencing technology from Oxford Nanopore is being applied to real-world tumour samples, including prostate, breast, ovarian and other rare cancers, to resolve cryptic genomic events that could not be fully characterized using conventional sequencing approaches. The session will also demonstrate how haplotype phasing, direct methylation detection and structural variant analysis are providing deeper biological insights into tumour-suppressor inactivation, as well as revealing potentially clinically relevant compound oncogenic alleles and improving confidence in the interpretation of both somatic and germline variants.
Learn how:
• Long-read nanopore sequencing enables haplotype phasing, improving the interpretation of complex cancer genomes
• Combining multiple approaches in a single experiment can provide a more complete understanding of genomic alterations in tumours
• Adaptive sequencing can improve research workflow efficiency and reduce costs
Unable to join the live event? Watch on demand. Register now to ensure that you receive information on how to gain access after the live event.
This webcast has been produced by Oxford Nanopore Technologies, who retains sole responsibility for content. About this content.
Oxford Nanopore Technologies products are RUO. Products labelled/branded as Oxford Nanopore Diagnostics may be RUO or may be regulated as in-vitro diagnostic devices in some jurisdictions, please check individual product labelling. Oxford Nanopore Technologies present the materials of third parties within the user community acknowledging that those materials belong to and are the true statements and representations of those third parties. Oxford Nanopore Technologies make no endorsements of the materials shown and the statements made.
Speakers
Dan Robinson, Associate Research Professor, Michigan Center for Translational Pathology, University of Michigan
Dr Dan Robinson is the Director of the MI-ONCOSEQ clinical sequencing laboratory. His main interest is advancing precision oncology and cancer genomics through integrative sequencing and analyses of DNA and RNA using advanced technologies.
Anantha Poluri, Associate Director, Regional Marketing, Oxford Nanopore Technologies
Anantha Poluri is Associate Director of Regional Marketing at Oxford Nanopore Technologies. She brings more than 24 years of experience across genomics and life sciences, spanning R&D, sales, product management and product marketing. Anantha holds a PhD in Molecular Virology and Microbiology from Baylor College of Medicine, where her research focused on advancing HIV-based lentiviral vector design for gene therapy.
Moderator
Alison Halliday, Freelance Science Writer
Alison Halliday, PhD, is a freelance science writer, focusing on life sciences, biomedicine and health stories. Following her doctorate at the University of Newcastle and postdoctoral research into human molecular genetics at University College London, she moved into science communications. With more than 25 years of experience spanning academia, industry and non-profit sectors – including a decade at Cancer Research UK – she has collaborated with Nature Research Custom Media since 2019.
